A diabetes, heart failure, and kidney disease medication is the first of its kind to significantly reduce both heart attacks and strokes Post author:admin Post published:February 18, 2025 Post category:uncategorized New research shows sotagliflozin is the only drug in its class to demonstrate these results. You Might Also Like AI model predicts Alzheimer’s progression with new insights into racial and sex-based disparities November 5, 2024 UCLA study reveals key signs for genetic testing in neurodevelopment disorders October 13, 2024 Study links epigenetic mechanism to placental blood vessel development January 15, 2025
AI model predicts Alzheimer’s progression with new insights into racial and sex-based disparities November 5, 2024